These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 20888328)

  • 1. The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats.
    Walsh S; Gorman AM; Finn DP; Dowd E
    Brain Res; 2010 Dec; 1363():40-8. PubMed ID: 20888328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in L-DOPA-treated rats.
    Azkona G; Sagarduy A; Aristieta A; Vazquez N; Zubillaga V; Ruíz-Ortega JA; Pérez-Navarro E; Ugedo L; Sánchez-Pernaute R
    Neuropharmacology; 2014 Apr; 79():726-37. PubMed ID: 24333147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias.
    Ferrer B; Asbrock N; Kathuria S; Piomelli D; Giuffrida A
    Eur J Neurosci; 2003 Sep; 18(6):1607-14. PubMed ID: 14511339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors.
    Morgese MG; Cassano T; Cuomo V; Giuffrida A
    Exp Neurol; 2007 Nov; 208(1):110-9. PubMed ID: 17900568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of PPAR gamma receptors reduces levodopa-induced dyskinesias in 6-OHDA-lesioned rats.
    Martinez AA; Morgese MG; Pisanu A; Macheda T; Paquette MA; Seillier A; Cassano T; Carta AR; Giuffrida A
    Neurobiol Dis; 2015 Feb; 74():295-304. PubMed ID: 25486547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia.
    Bézard E; Muñoz A; Tronci E; Pioli EY; Li Q; Porras G; Björklund A; Carta M
    Neurosci Res; 2013 Dec; 77(4):242-6. PubMed ID: 24135129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Arachidonyl-2'-chloroethylamide (ACEA), a synthetic agonist of cannabinoid receptor, increases CB
    Leija-Salazar M; Bermúdez de León M; González-Horta A; González-Hernández B
    Pharmacol Biochem Behav; 2020 Jul; 194():172950. PubMed ID: 32413434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats.
    Mela F; Millan MJ; Brocco M; Morari M
    Neuropharmacology; 2010 Feb; 58(2):528-36. PubMed ID: 19733554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease.
    van der Stelt M; Fox SH; Hill M; Crossman AR; Petrosino S; Di Marzo V; Brotchie JM
    FASEB J; 2005 Jul; 19(9):1140-2. PubMed ID: 15894565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism.
    Larramendy C; Taravini IR; Saborido MD; Ferrario JE; Murer MG; Gershanik OS
    Behav Brain Res; 2008 Dec; 194(1):44-51. PubMed ID: 18638507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Gutiérrez-Valdez AL; García-Ruiz R; Anaya-Martínez V; Torres-Esquivel C; Espinosa-Villanueva J; Reynoso-Erazo L; Tron-Alvarez R; Aley-Medina P; Sánchez-Betancourt J; Montiel-Flores E; Avila-Costa MR
    Behav Pharmacol; 2013 Dec; 24(8):640-52. PubMed ID: 24196024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias.
    Rascol O; Fox S; Gasparini F; Kenney C; Di Paolo T; Gomez-Mancilla B
    Parkinsonism Relat Disord; 2014 Sep; 20(9):947-56. PubMed ID: 24951359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for a role for α6(∗) nAChRs in l-dopa-induced dyskinesias using Parkinsonian α6(∗) nAChR gain-of-function mice.
    Bordia T; McGregor M; McIntosh JM; Drenan RM; Quik M
    Neuroscience; 2015 Jun; 295():187-97. PubMed ID: 25813704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa/benserazide microspheres reduced levodopa-induced dyskinesia by downregulating phosphorylated GluR1 expression in 6-OHDA-lesioned rats.
    Yang X; Chen Y; Hong X; Wu N; Song L; Yuan W; Liu Z
    Drug Des Devel Ther; 2012; 6():341-7. PubMed ID: 23185117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.
    Thornton E; Hassall MM; Corrigan F; Vink R
    Parkinsonism Relat Disord; 2014 May; 20(5):508-13. PubMed ID: 24637127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease.
    Segovia G; Mora F; Crossman AR; Brotchie JM
    Mov Disord; 2003 Feb; 18(2):138-49. PubMed ID: 12539206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
    Iderberg H; McCreary AC; Varney MA; Kleven MS; Koek W; Bardin L; Depoortère R; Cenci MA; Newman-Tancredi A
    Exp Neurol; 2015 Sep; 271():335-50. PubMed ID: 26037043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
    Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
    Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BN82451 attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease.
    Spinnewyn B; Mautino G; Marin JG; Rocher MN; Grandoulier AS; Ferrandis E; Auguet M; Chabrier PE
    Neuropharmacology; 2011 Mar; 60(4):692-700. PubMed ID: 21129389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.